FIELD: medicine.
SUBSTANCE: invention describes prednisolone metasulfobenzoate composition of controlled released within large intestine, containing sodium prednisolone metasulfobenzoate, hyaloid amylase coated, ethylcellulose and dibutyl-sebacate with ratio amylase to ethylcellulose 1:3.5 to 1:4.5, and amylase is wheat or corn amylase. Method of composition making is provided as well.
EFFECT: directed released of sodium prednisolone metasulfobenzoate in large intestine at low systemic action and no systemic by-effects.
12 cl, 2 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION WITH CONTROLLED RELEASE | 2003 |
|
RU2336865C2 |
| COMPOSITION EXHIBITING THE DELAYED (PROLONGED) RELEASING | 1990 |
|
RU2093148C1 |
| COATING COMPOSITION CONTAINING STARCH | 2007 |
|
RU2440104C2 |
| PHARMACEUTICAL FORM FOR DRUG DELIVERY TO THE COLON | 2007 |
|
RU2646825C2 |
| DRUG FORM FOR DELIVERY OF MEDICATION INTO LARGE INTESTINE | 2007 |
|
RU2478372C2 |
| ORAL CHOLESTYRAMINE COMPOSITION AND APPLICATION THEREOF | 2017 |
|
RU2750944C2 |
| CHOLESTYRAMINE PELLETS, ORAL CHOLESTYRAMINE COMPOSITIONS AND THEIR USE | 2018 |
|
RU2782016C2 |
| MEDICINAL FORMS ON BASIS OF BIPHOSPHONATES | 2005 |
|
RU2359678C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY INTESTINAL DISEASES (IID) | 2010 |
|
RU2561040C2 |
| ORAL CHOLESTYRAMINE COMPOSITION AND APPLICATION THEREOF | 2017 |
|
RU2750937C2 |
